Objective. To determine the genotype frequencies of β2- adrenergic receptor (β2AR) gene polymorphisms (Gly16Arg, Glu27Gln) in patients with fibromyalgia syndrome (FM) by comparison with unrelated healthy controls. We sought any clinical association with these polymorphisms and determined whether the polymorphisms would associate with a biologic guanosine protein-coupled stimulator receptor (Gs) dysfunction in FM. Methods. Study subjects included 97 clinically characterized patients with FM and 59 controls. The β2AR polymorphisms at codons 16 and 27 were determined using polymerase chain reaction-restriction fragment length polymorphism. The Gs functions of peripheral blood mononuclear cells (PBMC) were tested using isoproterenol (ISO) as the adrenergic Gs ligand and measuring intracellular cyclic adenosine monophosphate (cAMP) levels. Results. The frequency of the β2AR gene polymorphism Gly16Arg in FM (43.5%) was significantly lower than in controls (63.2%), suggesting that this genotype might have some effect on the risk of developing FM. The only clinical association in FM was with sleep dysfunction. Patients with FM who carried the β2AR polymorphism Arg16Arg also exhibited significantly lower PBMC basal cAMP levels (p < 0.05) and lower ISO-stimulated cAMP levels (p < 0.05) than FM carrying Gly16Gly or Gly16Arg. Conclusion. This confirms a relationship between β2AR polymorphism and FM. It is the first study to demonstrate β2AR polymorphism-related differences in intracellular cAMP responses of FM PBMC after β2AR stimulation in vitro. These findings may explain some of the differences in responsiveness of FM subgroups to the adrenergic agonist medications currently approved for FM treatment.
- Fibromyalgia syndrome
- Guanosine protein-coupled stimulator receptor
- Single-nucleotide polymorphisms
- β-adrenergic receptor
ASJC Scopus subject areas
- Immunology and Allergy